Yes, clinical trials have shown that GLP-1 medications can lower cardiovascular risks among individuals with obesity and atherosclerotic vascular disease
Routine monitoring is particularly important for patients with hypertension, hypotension, or cardiovascular disease
J Musculoskelet Neuronal Interact 21:142148 Cheng Y, Liu P, Xiang Q, Liang J, Chen H, Zhang H, Yang L (2022) Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway
Compounding pharmacies create these medications by combining, mixing, or altering ingredients to meet specific patient needs
Patient achieved 5 to 10% weight loss on semaglutide but weight has stalled for 12+ weeks